Trials / Recruiting
RecruitingNCT07293754
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Repertoire Immune Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPTR-1-201 | RPTR-1-201 |
| DRUG | PD-1 / PD-L1 monoclonal antibody | PD-1/PD-L1 monoclonal antibody |
Timeline
- Start date
- 2025-12-12
- Primary completion
- 2028-12-15
- Completion
- 2029-04-15
- First posted
- 2025-12-19
- Last updated
- 2026-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07293754. Inclusion in this directory is not an endorsement.